The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Selective serotonin reuptake inhibitors for premenstrual syndrome
Open accessAbstract
BACKGROUND: Premenstrual syndrome (PMS) is a common cause of physical, psychological and social problems in women of reproductive age. The key characteristic of PMS is the timing of symptoms, which occur only during the two weeks leading up to menstruation (the luteal phase of the menstrual cycle). Selective serotonin reuptake inhibitors (SSRIs) are increasingly used as first line therapy for PMS. SSRIs can be taken either in the luteal phase or else continuously (every day). SSRIs are generally considered to be effective for reducing premenstrual symptoms but they can cause adverse effects. OBJECTIVES: The objective of this review was to evaluate the effectiveness and safety of SSRIs for treating premenstrual syndrome. SEARCH METHODS: Electronic searches for relevant randomised controlled trials (RCTs) were undertaken in the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, PsycINFO, and CINAHL (February 2013). Where insufficient data were presented in a report, attempts were made to contact the original authors for further details. SELECTION CRITERIA: Studies were considered in which women with a prospective diagnosis of PMS, PMDD or late luteal phase dysphoric disorder (LPDD) were randomised to receive SSRIs or placebo for the treatment of premenstrual syndrome. DATA COLLECTION AND ANALYSIS: Two review authors independently selected the studies, assessed eligible studies for risk of bias, and extracted data on premenstrual symptoms and adverse effects. Studies were pooled using random-effects models. Standardised mean differences (SMDs) with 95% confidence intervals (CIs) were calculated for premenstrual symptom scores, using separate analyses for different types of continuous data (that is end scores and change scores). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Analyses were stratified by type of drug administration (luteal or continuous) and by drug dose (low, medium, or high). We calculated the number of women who would need to be taking a moderate dose of SSRI in order to cause one additional adverse event (number needed to harm: NNH). The overall quality of the evidence for the main findings was assessed using the GRADE working group methods. MAIN RESULTS: Thirty-one RCTs were included in the review. They compared fluoxetine, paroxetine, sertraline, escitalopram and citalopram versus placebo. SSRIs reduced overall self-rated symptoms significantly more effectively than placebo. The effect size was moderate when studies reporting end scores were pooled (for moderate dose SSRIs: SMD -0.65, 95% CI -0.46 to -0.84, nine studies, 1276 women; moderate heterogeneity (I(2) = 58%), low quality evidence). The effect size was small when studies reporting change scores were pooled (for moderate dose SSRIs: SMD -0.36, 95% CI -0.20 to -0.51, four studies, 657 women; low heterogeneity (I(2)=29%), moderate quality evidence).SSRIs were effective for symptom relief whether taken only in the luteal phase or continuously, with no clear evidence of a difference in effectiveness between these modes of administration. However, few studies directly compared luteal and continuous regimens and more evidence is needed on this question.Withdrawals due to adverse effects were significantly more likely to occur in the SSRI group (moderate dose: OR 2.55, 95% CI 1.84 to 3.53, 15 studies, 2447 women; no heterogeneity (I(2) = 0%), moderate quality evidence). The most common side effects associated with a moderate dose of SSRIs were nausea (NNH = 7), asthenia or decreased energy (NNH = 9), somnolence (NNH = 13), fatigue (NNH = 14), decreased libido (NNH = 14) and sweating (NNH = 14). In secondary analyses, SSRIs were effective for treating specific types of symptoms (that is psychological, physical and functional symptoms, and irritability). Adverse effects were dose-related.The overall quality of the evidence was low to moderate, the main weakness in the included studies being poor reporting of methods. Heterogeneity was low or absent for most outcomes, though (as noted above) there was moderate heterogeneity for one of the primary analyses. AUTHORS' CONCLUSIONS: SSRIs are effective in reducing the symptoms of PMS, whether taken in the luteal phase only or continuously. Adverse effects are relatively frequent, the most common being nausea and asthenia. Adverse effects are dose-dependent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Vitex agnus castus for premenstrual syndrome
Shaw, S., Wyatt, K. M., Campbell, J., Ernst, E., & Coon, J. T. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004632 · Cited by 3
Self-citationRetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Fluoxetine in the Treatment of Premenstrual Dysphoria
Steiner, M., Steinberg, S., Stewart, D., Carter, D., Berger, C., Reid, R., Grover, D., & Streiner, D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322301 · Cited by 445
Progesterone metabolite allopregnanolone in women with premenstrual syndrome
RAPKIN, A., MORGAN, M., GOLDMAN, L., BRANN, D., SIMONE, D., & MAHESH, V (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00417-1 · Cited by 376
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review
Dimmock, P. W., Wyatt, K. M., Jones, P. W., & O'Brien, P. S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02754-9 · Cited by 368
Self-citation
Cited by
Management of functional somatic syndromes
Henningsen, P., Zipfel, S., & Herzog, W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60159-7 · Cited by 741
Yonkers, K. A., O'Brien, P. S., & Eriksson, E. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60527-9 · Cited by 541
Self-citationSelective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Management of functional somatic syndromes and bodily distress
Henningsen, P., Zipfel, S., Sattel, H., & Creed, F. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000484413 · Cited by 335
Premenstrual Dysphoric Disorder: Epidemiology and Treatment
Hantsoo, L., & Epperson, C. N. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0628-3 · Cited by 329
Yonkers, K. A., & Simoni, M. K. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.05.045 · Cited by 323
O’Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E., Halbreich, U., Ismail, K. M. K., et al. (2011) · Archives of Women's Mental Health · doi:10.1007/s00737-010-0201-3 · Cited by 295
Self-citationSundström Poromaa, I., & Gingnell, M. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00380 · Cited by 291
Premenstrual Syndrome and Premenstrual Dysphoric Disorder
Braverman, P. K. (2007) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2006.10.007 · Cited by 288
Pearlstein, T. B., Bachmann, G. A., Zacur, H. A., & Yonkers, K. A. (2005) · Contraception · doi:10.1016/j.contraception.2005.08.021 · Cited by 279
Coffee, Caffeine, and Risk of Depression Among Women
Lucas, M. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.393 · Cited by 270
Bidirectional association between depression and obesity in middle–aged and older women
Pan, A., Sun, Q., Czernichow, S., Kivimaki, M., Okereke, O. I., Lucas, M., Manson, J. E., Ascherio, A., & Hu, F. B. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.111 · Cited by 264
ISPMD consensus on the management of premenstrual disorders
Consensus Group of the International Society for Premenstrual Disorders, Nevatte, T., O’Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E. W., et al. (2013) · Archives of Women s Mental Health · doi:10.1007/s00737-013-0346-y · Cited by 211
Anxiety Disorders Among Women: A Female Lifespan Approach
Hantsoo, L., & Epperson, C. N. (2017) · Focus · doi:10.1176/appi.focus.20160042 · Cited by 183
Kleinstäuber, M., Witthöft, M., & Hiller, W. (2012) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-012-9299-y · Cited by 94
MacKenzie, G., & Maguire, J. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3423-z · Cited by 84
Treatment of premenstrual dysphoric disorder
Rapkin, A. J., & Lewis, E. I. (2013) · Women s Health · doi:10.2217/whe.13.62 · Cited by 78
Bannbers, E., Gingnell, M., Engman, J., Morell, A., Comasco, E., Kask, K., Garavan, H., Wikström, J., & Sundström Poromaa, I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.006 · Cited by 70
Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications
Caldara, M., & Marmiroli, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090915 · Cited by 54
Empirically supported use of psychiatric medications in adolescents and adults with IBD
Thorkelson, G., Bielefeldt, K., & Szigethy, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000734 · Cited by 39
Metadata
- Authors
- Marjoribanks, J., Brown, J., O'Brien, P. M. S., & Wyatt, K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-06-07
- Issue
- 6
- Pages
- CD001396-CD001396
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2116594963
- Cited by
- 413
- References
- 104
- FWCI
- 28.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.